Petrichor Healthcare Capital Management

Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

Leukocare is a company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation in patients undergoing cardiac surgery. It offers innovative formulation technologies that leverage bioinformatics and artificial intelligence for the improvement of biopharmaceuticals, viral vectors, and vaccines. Additionally, the company specializes in biofunctionalized devices that help decrease leukocyte activity in extracorporeal blood circuits using antibodies. Leukocare intends to utilize its funding to advance market access efforts for several development projects based on its Stabilizing and Protecting Solutions (SPS®) across various fields, including vaccines, biopharmaceuticals, and combination devices.

Leukocare is a company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation in patients undergoing cardiac surgery. It offers innovative formulation technologies that leverage bioinformatics and artificial intelligence for the improvement of biopharmaceuticals, viral vectors, and vaccines. Additionally, the company specializes in biofunctionalized devices that help decrease leukocyte activity in extracorporeal blood circuits using antibodies. Leukocare intends to utilize its funding to advance market access efforts for several development projects based on its Stabilizing and Protecting Solutions (SPS®) across various fields, including vaccines, biopharmaceuticals, and combination devices.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, founded in 2004. The company specializes in the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. ITM offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for nuclear medicine, and radionuclides like 225Ac and 213Bi for next-generation targeted therapies. Additionally, it provides automated systems for the preparation of radiolabeled biomolecules and various GMP radiolabeling services. ITM is actively developing a portfolio of treatments aimed at various cancers, including neuroendocrine tumors and bone metastases, with a focus on improving patient outcomes and quality of life while minimizing side effects. The company has established a robust global supply network and has received marketing authorization for some of its products, marking significant progress in its mission to advance targeted radionuclide therapies in precision oncology.

ClearPoint Neuro, formerly known as MRI Interventions, is a medical technology company focused on advancing therapies for complex neurological disorders. The company's mission is to enhance the quality of life for patients and their families by enabling precise treatment options. ClearPoint Neuro's current product offerings include solutions for deep-brain stimulation and biopsy procedures. The company is also developing future applications that encompass laser ablation, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies directly to the brain. Through its innovative platform, ClearPoint Neuro aims to provide effective and targeted interventions in the field of neurology.

ClearPoint Neuro, formerly known as MRI Interventions, is a medical technology company focused on advancing therapies for complex neurological disorders. The company's mission is to enhance the quality of life for patients and their families by enabling precise treatment options. ClearPoint Neuro's current product offerings include solutions for deep-brain stimulation and biopsy procedures. The company is also developing future applications that encompass laser ablation, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies directly to the brain. Through its innovative platform, ClearPoint Neuro aims to provide effective and targeted interventions in the field of neurology.

Persivia Inc. is a healthcare technology company that provides an AI-driven platform designed to assist healthcare providers in managing value-based care programs. Founded in 2005 and headquartered in Marlborough, Massachusetts, Persivia specializes in chronic care management and clinical analytics, catering to Accountable Care Organizations (ACOs) and Patient-Centered Medical Homes (PCMH). The company's SaaS-based platform integrates clinical, socioeconomic, and claims data, offering a comprehensive view that places patients at the center of care. This technology delivers advanced analytics and real-time clinical decision support, enabling healthcare professionals to enhance care quality, improve patient outcomes, and navigate government regulations effectively.

CorneaGen is dedicated to advancing cornea care through the development of innovative medical devices, biologics, and therapeutic interventions aimed at eliminating corneal blindness. The company focuses on transforming the practices of corneal surgeons by providing a comprehensive range of services, including high-quality tissue delivery, surgeon education, and advocacy for patient access and reimbursement. By equipping eye surgeons with the latest tools and resources, CorneaGen enhances their ability to restore sight and improve patient outcomes for those affected by corneal conditions.